HOUSTON, Nov. 20, 2019 /PRNewswire/ -- CNS
Pharmaceuticals, Inc. (NASDAQ: CNSP) ("Company"), a biotechnology
company specializing in the development of novel treatments for
brain tumors, today announced Chief Executive Officer of CNS
Pharmaceuticals, John M. Climaco,
along with founder, Waldemar Priebe,
PhD, and members of management, including, Chief Medical Officer,
Sandra Silberman, MD, PhD, Chief
Scientific Officer, Donald Picker,
PhD, and scientific advisory board member, Sigmund Hsu, MD, PhD, will be attending the
24th Annual Meeting of the Society of Neuro-Oncology
("SNO"). The event will take place November
20-24, 2019 at the JW Marriott Desert Ridge Resort in
Phoenix, Arizona.
"Following our recent IPO, we are looking forward to connecting
with the scientific community at the world's largest neuro-oncology
conference," stated John Climaco.
"We remain committed to further pursuing the advancement of our
novel anthracycline, Berubicin, and to developing therapies for the
treatment of glioblastoma."
About Berubicin
Berubicin is an anthracycline, a class
of drugs among the most powerful chemotherapy drugs and effective
against more types of cancer than any other class of
chemotherapeutic agents. Anthracyclines are designed to damage the
DNA of targeted cancer cells by interfering with the action of the
topoisomerase II, a critical enzyme enabling cell proliferation.
Berubicin was developed at the MD Anderson Cancer Center (MDACC),
the world's largest cancer research facility. Berubicin appeared to
demonstrate one Durable Complete Response in a Phase I human
clinical trial conducted by a prior developer.
About CNS Pharmaceuticals Inc.
CNS Pharmaceuticals is a biotechnology company specializing in the
development of novel treatments for primary and metastatic brain
and central nervous system tumors. Its lead candidate Berubicin is
for the treatment of glioblastoma, a type of brain cancer currently
considered incurable, as well as pancreatic and ovarian cancers,
and lymphomas. The Company entered into an IP agreement with
Houston Pharmaceuticals, Inc. and a Purchase Agreement with Reata
Pharmaceuticals Inc. For more information, visit
www.cnspharma.com
Forward-Looking Statements
Some of the statements in
this release are forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, Section 21E of the
Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements relate to future events, future
expectations, plans and prospects. Although CNS believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. CNS has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Risk Factors" in the Form S-1 we filed
with the SEC on October 7, 2019. Any
forward-looking statements contained in this release speak only as
of its date. CNS undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/cns-pharmaceuticals-announces-attendance-at-the-24th-annual-meeting-of-the-society-of-neuro-oncology-300961935.html
SOURCE CNS Pharmaceuticals, Inc.